Durable melanoma control following disseminated talimogene laherparepvec herpetic infection

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection

Bibliographic Details
Main Authors:	Leonid Shmuylovich, MD, PhD, Aubriana M. McEvoy, MD, MS, Ryan C. Fields, MD, Leonel Hernandez-Aya, MD, George Ansstas, MD, David Y. Chen, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2022-11-01
Series:	JAAD Case Reports
Subjects:	disseminated herpes infection durable response melanoma talimogene laherparepvec T-VEC
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512622004325

Similar Items

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec
by: Jamie Lebhar, BME, et al.
Published: (2023-10-01)

Locoregional melanoma metastases resistant to PD-1 inhibitor therapy treated with intralesional talimogene laherparepvec
by: Matthew M. Wallace, MD, et al.
Published: (2024-01-01)

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01)

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient
by: Kelsey E. Hirotsu, MD, et al.
Published: (2021-07-01)

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec
by: Jonathan T. Blackmon, et al.
Published: (2017-07-01)

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC)
by: Jennifer Gardner, et al.
Published: (2018-07-01)

Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01)

Talimogene laherparepvec: First in class oncolytic virotherapy
by: Robert M. Conry, et al.
Published: (2018-04-01)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311)
by: Sant P. Chawla, et al.
Published: (2023-05-01)

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
by: Robert H. I. Andtbacka, et al.
Published: (2019-06-01)

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
by: Jens Tijtgat, et al.
Published: (2021-10-01)

Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01)

Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
by: Max Miller, et al.
Published: (2023-06-01)

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors
by: Lucas Moreno, et al.
Published: (2023-05-01)

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab
by: David M. Miller, et al.
Published: (2018-11-01)

Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers
by: Dimitrios C. Ziogas, et al.
Published: (2022-06-01)

Efficacy of Oncolytic Herpes Simplex Virus T-VEC Combined with BET Inhibitors as an Innovative Therapy Approach for NUT Carcinoma
by: Paul V. Ohnesorge, et al.
Published: (2022-06-01)

Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
by: Howard L. Kaufman, et al.
Published: (2017-09-01)

Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
by: Ibrahim Ragab Eissa, et al.
Published: (2017-07-01)

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial
by: Maartje W. Rohaan, et al.
Published: (2022-08-01)

Resolution of metastatic neck nodes associated with a periauricular cutaneous squamous cell carcinoma after intranodal injection of talimogene laherparepvec
by: Yonglu Che, MD, PhD, et al.
Published: (2024-04-01)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy
by: Tiantian Zhang, et al.
Published: (2023-01-01)

Clitoral metastasis of vulvar melanoma treated with talimogene laherparepvec
by: Erin M. McClure, BS, et al.
Published: (2023-02-01)

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1
by: Markus eMoehler, et al.
Published: (2014-05-01)

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma
by: Kate E. Beekman, BS, et al.
Published: (2023-03-01)

Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec
by: Neha Singh, BS, et al.
Published: (2023-06-01)

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class
by: Howard L. Kaufman, et al.
Published: (2022-02-01)

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment
by: Jennifer Gardner, et al.
Published: (2022-10-01)

Rosacea fulminans herpeticum: Rosacea fulminans with superimposed herpetic infection
by: Aaron Tisack, BS, et al.
Published: (2021-05-01)

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context
by: Robert H.I. Andtbacka, et al.
Published: (2019-09-01)

Herpetic geometric glossitis presenting as vegetative plaques in the context of acquired immunodeficiency syndrome
by: Leslie Elizabeth Rocha-Méndez, MD, et al.
Published: (2021-06-01)

Antiviral-Resistant Fulminant Herpes Hepatitis in Pregnancy
by: Christina A. Herrera, et al.
Published: (2013-05-01)

409 A phase i trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO)
by: John Stewart, et al.
Published: (2020-11-01)

Bespoke circulating tumor DNA as a biomarker for treatment response in a refractory Merkel cell carcinoma patient
by: John Yeakel, MD, et al.
Published: (2021-12-01)

Prophylaxis of herpetic infections reactivation before the planned pregnancy
by: V. S. Kopcha, et al.
Published: (2018-07-01)

Post Herpetic Osteonecrosis of the Maxilla
by: Giridhar Naidu, et al.
Published: (2019-05-01)

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Published: (2021-10-01)

Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response
by: Pablo Iglesias, et al.
Published: (2018-11-01)

Herpetic stomatitis development mechanism in patients with tonsillitis
by: Khlamova O.G., et al.
Published: (2012-03-01)

Disseminated-cutaneous sporotrichosis in an immunocompetent adult
by: Briana M. Garcia, BS, et al.
Published: (2021-05-01)